Dexcom authorizes $700M share repurchase program through June 30, 2023

DEXCOM INC

Board committee approved a share repurchase program for up to $700M of outstanding common stock.
Repurchase period ends no later than June 30, 2023; timing depends on market conditions.
Repurchases may be made on open market or in privately negotiated transactions; no obligation to repurchase any amount.
Program may be extended, modified, suspended, or discontinued at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.